Grzegorz Kopeć
Grzegorz Kopeć is an expert in Cardiology at John Paul II Hospital (Poland). As of October 2026, ScienceLeadR ranks Grzegorz Kopeć in the top 1% of experts worldwide for Hypertension and Hypertension, Pulmonary. Grzegorz Kopeć has authored 285 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 2 of them ongoing. SLR score: 1,069 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Pulmonology - Internal Medicine - Transplantation
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2006 - 2026
Number : 285
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Early and long-term outcomes and their predictors in incident pulmonary arterial hypertension: Results from the Database of Pulmonary Hypertension in Poland (BNP-PL). PMID 42708552 — heart defects, congenital, registries, hypertension, comorbidity, mortality, hypertension, pulmonary, heart diseases, hospitalization, heart, connective tissue, cardiovascular system, connective tissue diseases, cardiology, pulmonary arterial hypertension, diagnosis, therapeutics, tissues | Kardiol Pol | 2026 | 0 |
| Outcomes of catheter-directed mechanical thrombectomy in patients with cancer-associated pulmonary embolism: a multicenter, prospective registry. PMID 42657006 — registries, mortality, embolism, safety, hemorrhage, neoplasms, hospital mortality, pulmonary embolism, morbidity, thrombectomy, catheters | Res Pract Thromb Haemost | 2026 | 1 |
| Cardiology referral for suspected pulmonary arterial hypertension: Unmet needs and diagnostic barriers in primary care. PMID 42591006 — hypertension, cardiovascular system, cardiology, pulmonary arterial hypertension | Kardiol Pol | 2026 | 0 |
| Thrombophilias associated with patent foramen ovale (PFO) in patients after an episode of cryptogenic stroke. PMID 42583727 — foramen ovale, patent, stroke, cardiovascular diseases, thrombophilia, mutation, ischemia, foramen ovale | Future Cardiol | 2026 | 0 |
| Effectiveness of PAH Specific Treatment Is Comparable Between PAH Associated With Connective Tissue Disease and Idiopathic PAH: Data From the Multicentre National Registry. PMID 42516678 — registries, mortality, connective tissue, connective tissue diseases, therapeutics, tissues | Pulm Circ | 2026 | 0 |
Clinical Studies 7
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients NCT06317805 — familial primary pulmonary hypertension, epoprostenol, phosphodiesterase 5 inhibitors, hypertension, hypertension, pulmonary, phosphoric diester hydrolases, safety, endothelins, glass, solutions, pulmonary arterial hypertension, infusion pumps, maximum tolerated dose, bosentan, cyclic nucleotide phosphodiesterases, type 5, therapeutics, endothelin receptor antagonists, hemodynamics, receptors, endothelin, tadalafil | Phase 4 | Recruiting | 2023 |
| Ultrasound facilitated Catheter directed Thrombolysis in Intermediate high Risk Pulmonary Embolism NCT04790370 — embolism, blood, fibrinolysis, heparin, pulmonary embolism, therapeutics, heparin, low-molecular-weight, random allocation, catheters | Phase 4 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map